Seth M. Pollack

Join us in person @LurieCancer tomorrow, Fri. July 11, for our 2025 Oncology Review — a comprehensive summary of key research findings and emerging data in clinical care, presented by our experts. View the details & agenda and register now: cancer.northwestern.edu/events/profess… #CME

#ASCO25 Today at 11:30 AM - Nadeem Bilani, MD, of @LurieCancer will present a clinical and genomic landscape analysis of GI stromal tumors during the Sarcoma Rapid Oral Abstract Session. Hall S504. Abstract #11512. Don't miss it! @BilaniMD #GIST

Congratulations to Nadeem Bilani, MD, @BilaniMD, on receiving a 2025 Merit Award from @ASCO’s @ConquerCancerFd in recognition of your work! @immunosarc @NUFeinbergMed @NU_IntMed

Watch @breelynwilkyMD, of @CUCancerCenter, @JasonSicklick of @UCSD and @immunosarc of @NUFeinbergMed discuss the biological mechanisms of resistance in GIST, differentiating between primary and secondary resistance. Watch the full discussion here: hubs.li/Q03nKB8F0

Love @OncLive @breelynwilkyMD #GIST : onclive.com/insights/my-tr…

We are looking for another #sarcoma Medical Oncologist to join our team in downtown Chicago!! Graduating fellows: you are interested in an academic position in Chicago, we can train you up on the sarcoma part of the job! job is now posted: facultyrecruiting.northwestern.edu

Dr. Pedro Antonio Hermida de Viveiros will discuss the phase 2 trial of zanzalintinib for leiomyosarcoma patients at @NorthwesternMed in a free webinar 7 pm EST Feb. 12. Register here: us02web.zoom.us/meeting/regist…. This is presented by LMSDR.org & open to everyone.

Northwestern sarcoma holiday party 2024!!!!!! Great party for sarcoma research and clinical teams. Thanks to Pablo Penaloza lab and Jenn Wu’s lab (we got r01’s with both in 2024) Come work with us! My lab is hiring!! Also we are hiring another sarcoma med onc!! Join us!!

Important @luriecancer clinical trial led by the director of our translational research program @matei_dem on endometrial cancer, just published in JCO.

Cancer survivors are growing in number. In the US, nearly half of survivors have lived 10 or more years after diagnosis, while 19% have lived 20 or more years. The prevalence of long-term survivors is expected to increase through 2040. go.nih.gov/rOUbZJD #CancerSurvivorship

Thanks to @DrWGradishar and @ElsonRothschild for inviting me to deliver a Grand Rounds presentation this morning to the team of physicians at the Lurie Cancer Center & Hematology/Oncology @LurieCancer, and thanks to @immunosarc for the introduction. A great chance to explore…

@immunosarc joins #SARCTalk to share his insights on #clinicaltrials, #research, and advice for younger #researchers. You don't want to miss this episode, listen now! open.spotify.com/episode/36b31P… #sarcoma #SARCTrials #podcast

@immunosarc joins #SARCTalk to share his insights on #clinicaltrials, #research, and advice for younger #researchers. You don't want to miss this episode, listen now! open.spotify.com/episode/36b31P… #sarcoma #SARCTrials #podcast

Doxorubicin +/- pembro trial open now! Saw some impressive activity in the initial phase2, hopefully will be confirmed! ⁦@immunosarc⁩ #sarcoma #CTOS2024 ⁦@eaonc⁩

⁦@candace_haddox⁩ presenting SARC044 for patients with #GIST. Trial now open ⁦@DanaFarber⁩ #ctos

IO can be safe and effective for HIV-KS. CITN12: Pembrolizumab in HIV-Associated Kaposi Sarcoma | ⁦@JCO_ASCO⁩ ⁦@DrKateLurain⁩ ⁦@EladSharonMD⁩ ⁦@ThomasUldrick⁩ ascopubs.org/doi/10.1200/JC…

Great article about Dr. Fletcher, thepathologist.com/outside-the-la…, "People go through phases; quite a few have little or no self-doubt in their 30s or 40s and think that they know almost everything. Most of them, if they are smart, will eventually discover

USCAP was saddened to learn of the passing of Dr. Christopher D.M. Fletcher. Dr. Fletcher was an exceptional and innovative pathologist who dedicated many years in service to USCAP, including serving as President. He will be missed both personally and professionally.

It's shocking to realize he is gone. ❤️

If there is a 10-11% cut to the NCI budget, at a time that the RO1 paylines have been very bad for a long time, the consequences on cancer research will be catastrophic.